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Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates,
chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This article
reviews the ongoing clinical advances in the treatment of CLL in both previously untreated and relapsed disease
and focuses on the benefit of different therapeutic strategies, the most effective therapy combinations and the
potential activity of novel agents. Novel agents and combination therapies have been investigated by several
studies in both the upfront and relapsed setting, particularly for patients with 17p deletion, TP53 mutation and
fludarabine-refractory CLL. While these agents and combination therapies have improved initial response rates,
ongoing studies are continued to determine and improve the efficacy and safety. Despite advancements in the
treatment of CLL have led to high response rates, allogeneic hematopoietic stem cell transplantation (allo-HSCT)
remains the only curative option and reduced-intensity conditioning (RIC) allo-HSCT must be strongly considered
whenever feasible. As such, ongoing studies of these agents and other novel approaches in clinical development
are needed to expand and improve treatment options for CLL patients.
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Chronic lymphocytic leukemia (CLL) remains an incur-
able disease with an extremely variable course; survival
after diagnosis can range from months to decades [1].
Genomic features such as mutational status of immuno-
globulin heavy chain variable region genes (IGHV), ataxia
telangiectasia mutated (ATM) and TP53 tumor suppres-
sor genes, β2-microglobulin, zeta-chain-associated protein
kinase 70 (ZAP70) expression, interphase cytogenetics,
and complex karyotype on metaphase cytogenetics, pro-
vide further differentiation of disease prognosis [2]. As a
result, therapy must be flexible and tailored for different
patient groups [3]. With the improvement of its associated
prognostic and therapy response factors, the treatment of
CLL has dramatically changed. Focusing on the benefit of
different therapeutic strategies, this article reviews recent
advancements, the most effective therapy combinations* Correspondence: xinwang55@yahoo.com.cn
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reproduction in any medium, provided the orand potential activity of novel agent in the treatment
of CLL.Chemotherapy
Although chlorambucil gave lower overall response rates
(ORRs) and a shorter progression-free survival (PFS)
compared with the purine analogue fludarabine [4], chlor-
ambucil administered as front-line therapy to elderly
CLL patients ≥65 years proved as effective in sustaining
remissions as fludarabine (Table 1) [5]. Bendamustine, a
cytotoxic hybrid of an alkylating agent and a purine ana-
log, was introduced for the treatment of CLL in 2008 [6].
Based on the results of an open-label phase 3 trial in 319
previously untreated CLL patients, single-agent benda-
mustine has shown improved ORR and complete re-
sponse (CR) rate (68% and 31%) when compared with
chlorambucil (31% and 2%) [7]. The median PFS was
21.6 months with bendamustine and 8.3 months with
chlorambucil (P < 0.0001) (Table 1). A retrospective
chart review showed that bendamustine, either alone or
with rituximab, provided meaningful response rates and
was generally well tolerated in patients ≥70 years old
with CLL [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Phase 3 trials of chemotherapy in previously untreated CLL patients




CR,% ORR,% Median PFS
(months)
OS
Rai, 2000 [4] Chlorambucil 181 62 4 37 14 Median 56 m
Fludarabine 170 64 20 63 20 Median 66 m
Eichhorst, 2009 [5] Chlorambucil 100 70 0 51 18 Median 64 m
Fludarabine 93 71 7 72 19 Median 46 m
Knauf, 2009 [7] Chlorambucil 157 66 2 31 8.3 NR
Bendamustine 162 63 31 68 21.6 NR
Eichhorst, 2006 [9] Fludarabine 164 59 7 83 20 81% at 3 y
FC 164 58 24 94 48 80% at 3 y
Catovsky, 2007 [10] Fludarabine 194 64 15 80 23 52% at 5 y
FC 196 65 38 94 43 54% at 5 y
Chlorambucil 387 65 7 72 20 59% at 5 y
Flinn, 2007 [11] Fludarabine 137 61 5 60 19 80% at 2 y
FC 141 61 23 74 32 79% at 2 y
Robak, 2010 [13] CC 192 58 47 88 28 62.4% at 4 y
FC 203 59 46 82 27 60.6% at 4 y
Robak, 2011 [15] Cladribine 174 61 21 78 27.2 Median 45 m
CC 171 62 29 83 22.4 Median 48 m
CMC 163 59 36 80 25.6 Median 46 m
Abbreviations: CC, cladribine, cyclophosphamide; CMC, cladribine, cyclophosphamide, mitoxantrone; CR, complete response; FC, fludarabine, cyclophosphamide;
NR, not researched; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
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comparing fludarabine and cyclophosphamide (FC) with
fludarabine monotherapy showed superior CRs, ORRs
and PFS for the FC arm [3,9-11], while a analysis of the
subgroup of patients without high-risk genetic deletions
showed superior overall survival (OS), in these patients
comparing FC with fludarabine monotherapy [12]. A
randomized phase 3 trial showed that cladribine and flu-
darabine in combination with cyclophosphamide are
equally effective and safe first-line regimens for progres-
sive CLL. However, both combinations have unsatisfac-
tory activity in patients with 17p13 (TP53 gene) deletion
(Table 1) [13]. One trial of cladribine (C) versus cladri-
bine and cyclophosphamide (CC) versus cladribine,
cyclphosphamide plus mitoxantrone (CMC) showed
superior CRs for the CMC arm over C but not the CC
arm [14]. However, long term results for these patients
confirmed that cladribine alone, CC and CMC regimens
produced comparable PFS and OS in previously un-
treated progressive CLL (Table 1) [15].
Monoclonal antibodies
Rituximab
As the first approved therapeutic antibody for the treat-
ment of cancer, rituximab used in CLL has been exten-
sively explored. Numerous studies combining rituximab
with other therapies have been pursued, as summarizedin Table 2. In a randomized phase 2 study, a total of 104
patients were enrolled. Fludarabine with concurrent
rituximab (n = 51) was compared to fludarabine with se-
quential rituximab (n = 53) in untreated patients with
CLL [16]. After a median follow-up of 117 months
(range, 66 to 131 months), the median PFS and OS
times for the treatment groups were similar, with an
overall estimated median PFS of 42 months (95% CI, 31
to 46 months) and median OS of 85 months (95% CI, 71
to 95 months) [17]. These long-term data support flu-
darabine plus rituximab as one acceptable first-line
treatment for symptomatic patients with CLL.
The combination of pentostatin, cyclophosphamide,
and rituximab (PCR) achieved an ORR >90%, with >40%
CR in patients with untreated CLL [18]. Moreover, the
findings of a phase 2 trial suggested that increasing the
dose of the purine nucleoside analogue did not eliminate
the need for cyclophosphamide in chemoimmunotherapy
for the treatment of CLL [19]. A phase 3 trial compared
the combination of fludarabine, cyclophosphamide, and
rituximab (FCR) and PCR in previously untreated or
minimally treated B-cell CLL [20]. The infection rate
(FCR/PCR) was 31%/36%, 12 (14%)/6 (7%) patients
achieved CR; the ORR including CR, partial response
(PR), and nodular PR (nPR) was 59%/49%.
A phase 1/2 trial of fludarabine, bendamustine, and
rituximab (FBR) chemoimmunotherapy for previously
Table 2 Selected trials of chemoimmunotherapy with rituximab in CLL patients








Woyach, 2011 [17] FR (C) 2 51 Untreated 47 90 42 85
FR (S) 53 Untreated 28 77
Kay, 2007 [18] PCR 2 64 Untreated 41 91 32.6 Not Rep
Kay, 2010 [19] PR 2 33 Untreated 27 76 12 Not Rep
Reynolds, 2011 [20] PCR 3 92 20% Pretreated 7 49 NR NR
FCR 92 20% Pretreated 14 59 NR NR
Wierda, 2011 [21] FBR 1/2 14 Untreated 36 93 Not Rep Not Rep
Bosch, 2011 [23] R-FCM 2 72 Untreated 82 93 Not Rep Not Rep
Jenke, 2011 [24] CHOP-R 2 26 Pretreated, F-ref 0 54 11 27
15 Pretreated, RT 7 67 15 27
15 Pretreated, AIC 0 82 14 50
Abbreviations: AIC, autoimmune cytopenia; CHOP-R, cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab; CR, complete response; FBR,
fludarabine, bendamustine, and rituximab; FR (C), fludarabine, rituximab, concurrent; FR (S), fludarabine, rituximab, sequential; FCR, fludarabine, cyclophosphamide,
rituximab; F-ref, fludarabine-refractory; NR, not researched; Not Rep, not reported; ORR, overall response rate; OS, overall survival; PCR, penostatin
cyclophosphamide, rituximab; PFS, progression-free survival; R-FCM, rituximab, fludarabine, cyclophosphamide, mitoxantrone; RT: Richter’s transformation.
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was tolerated up to the highest bendamustine dose evalu-
ated with significant efficacy [21]. In another study,
retherapy with bendamustine, mitoxantrone and rituxi-
mab in patients with relapsed/refractory CLL and indo-
lent lymphomas also achieved high response rates [22].
Another chemoimmunotherapies with rituximab in CLL
patients were also studied in recent trials [23,24].
Alemtuzumab
As a recombinant monoclonal antibody that targets the
CD52 cell-surface antigen, alemtuzumab significantly
improved PFS, time to alternative treatment, ORR and
CR, and minimal residual disease-negative remissions in
previously untreated CLL patients, compared with chlor-
ambucil (Table 3) [25]. Furthermore, alemtuzumabTable 3 Selected trials of alemtuzumab monotherapy and che




Hillmen, 2007 [25] Alemtuzumab 3 149 Un
Chlorambucil 148 Un
Gritti, 2012 [27] Alemtuzumab 2 18 F-r
Stilgenbauer, 2011 [28] AD 2 30 Un
17 Re
40 F-r
Geisler, 2011 [29] AFC 3 129 Un
FC 133 Un
Badoux, 2011 [30] CFAR 2 80 Re
Zent, 2011 [31] PAR 2 19 Re
Abbreviations: A, alemtuzumab; AD, alemtuzumab and dexamethasone; AFC, alemt
cyclophosphamide, alemtuzumab and rituximab; CR, complete response; FC, fludara
NR, not researched; Not Rep, not reported; ORR, overall response rate; OS, overall sudemonstrated significant activity in patients with bulky
nodes, as evidenced by an ORR in patients with lymph
nodes ≥5 cm of 76% in alemtuzumab-treated patients
versus 44% in chlorambucil-treated patients (P = 0.0125).
Alemtuzumab also showed a promising safety profile
coupled with satisfactory effectiveness in poor prognosis
CLL [26,27]. The combination of alemtuzumab and oral
dexamethasone showed high response rates in elder
patients with ultra high-risk CLL, with promising prelim-
inary findings for PFS and OS. However, the improved
initial response by adding dexamethasone did not seem
to translate into improved long-term results, when com-
pared to the preceding CLL2H study with single agent
alemtuzumab (Table 3) [28].
Alemtuzumab based chemoimmunotherapy has also
shown good responses in relapsed/refractory diseasemoimmunotherapy in CLL patients
atment
tus




treated 24 83 14.6 NR
treated 2 55 11.7 NR
ef 8 44 10.3 29.1
treated, del(17p) 20 97 16.9 >24 , NR
lapse, del(17p) 0 76 10.4 15
ef 5 70 8.4 12
treated, high-risk 57 88 37 NR
treated, high-risk 45 80 31 NR
fractory /relapse 29 65 10.6 N/A
fractory /relapse 32 74 7 23
uzumab plus fludarabine and cyclophosphamide; CFAR, fludarabine,
bine and cyclophosphamide; F-ref, fludarabine-refractory; N/A, not applicable;
rvival; PAR, pentostatin, alemtuzumab, and rituximab.
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CLL trial recently indicated that chemoimmunotherapy
with low-dose subcutaneous alemtuzumab plus oral flu-
darabine and cyclophosphamide was safe and induced
more and deeper CRs in untreated patients with high-
risk CLL than chemotherapy with FC alone [29]. Good
response rates in highly pretreated high-risk group of
patients were indicated in a phase 2 study of alemtuzu-
mab plus FCR (CFAR), although there was no benefit in
survival outcomes [30]. Another study also indicated
that pentostatin, alemtuzumab, and low dose rituximab
was effective therapy for relapsed/refractory CLL/small
lymphocytic lymphoma (SLL) [31].
Final results of a phase 2 study in previously untreated
elderly CLL patients indicated that three courses of FC
only yielded a rather high response rate and a short
(8 weeks) alemtuzumab consolidation course could
thereafter be administered safely, leading to a 52% rate of
PR to CR switches, a high proportion of patients with un-
detectable blood MRD after the end of treatment and
durable responses. Overall, 26 patients were in CR after
the whole treatment strategy accounting for 51% of the
entire cohort [32]. In another study, Alemtuzumab con-
solidation for residual disease after treatment with high-
dose methylprednisolone plus rituximab (HDMP-R) was
well tolerated and effective in patients with CLL [33].
However, alemtuzumab consolidation did not improve
outcome for CLL patients with high risk genomic fea-
tures on successive Cancer and Leukemia Group B
(CALGB) trials [34].Ofatumumab
Ofatumumab is a fully humanized CD20 monoclonal
antibody that targets an epitope different from the epi-
tope targeted by rituximab. Based on the interim analysis
of the pivotal international clinical trial, which included
data from 138 CLL patients refractory to fludarabine
and alemtuzumab (FA-ref ) and refractory to fludarabine
but did not receive treatment with alemtuzumab due to
bulky disease (BF-ref ), ofatumumab had been approved
by the FDA for patients with CLL refractory to fludar-
abine and alemtuzumab in October 2009 [35]. At this
interim analysis, the ORR (primary endpoint) with
single-agent ofatumumab was 58% (99% CI: 40, 74) in
the FA-ref group and 47% (99% CI: 32, 62) in the BF-
ref group. The final results for the primary endpoint
of this study in 206 enrolled patients indicated that
the ORR was 51% for the FA-ref group and 44% for
the BF-ref group (Table 4) [36]. In another phase 2 trial
of ofatumumab for older patients and patients who
refused fludarabine-based regimens with previously
untreated CLL or SLL, 13 patients (44%) achieved an
objective response (CR, 0; PR, 13); 16 (53%) patients hadstable disease (SD); 1 patient (3%) had progressive disease
(PD) (Table 4) [37].
Front-line ofatumumab-based chemoimmunotherapy
appeared to be well-tolerated in patients with CLL. An
international phase 2 trial investigated the efficacy and
safety of 2 dose levels of ofatumumab combined with
fludarabine and cyclophosphamide (O-FC) in previously
untreated patients with CLL. In this trial, 61 patients
were randomized to the ofatumumab 500 mg (n = 31)
or 1000 mg (n = 30) dose cohorts. The CR rate was 32%
for the 500 mg and 50% for the 1000 mg cohort, and the
ORR was 77% and 73%, respectively. The most frequent
Common Terminology Criteria grade 3–4 investigator-
reported adverse events were neutropenia (48%),
thrombocytopenia (15%), anemia (13%), and infection
(8%) (Table 4) [38]. Another clinical trial has been
initiated to study the effect of ofatumumab in combin-
ation with pentostatin and cyclophosphamide (PCO) for
patients with previously untreated CLL (Table 4) [39].
Compared to the historic experience with rituximab-
based chemoimmunotherapy, ofatumumab-based che-
moimmunotherapy appeared to have less hematologic
toxicity and improved efficacy.Lumiliximab
Lumiliximab is a macaque-human primatized monoclo-
nal antibody that targets the CD23 antigen. In a phase 1
trial, investigators found that lumiliximab was well toler-
ated but showed minimal activity [40]. In a phase 1/2
trial, FCR plus lumiliximab resulted in an OR rate of
65% and a CR rate of 52%, and the toxicity of the com-
bination appeared no different from that which was pre-
viously reported with FCR in treatment of relapsed CLL
[41]. However, a phase 3 study comparing FCR to FCR
plus lumiliximab in relapsed CLL showed no benefit in
terms of improved response rate of PFS with the
addition of lumiliximab to FCR [42].Obinutuzumab
Obinutuzumab (GA101) is a humanized, third generation,
type II CD20 IgG1 antibody with a glycoengineered Fc
region [43]. It exhibits enhanced antibody-dependent
cellular cytotoxicity and superior caspase-independent
apotosis induction in comparison with classic type I
CD20 antibodies, such as rituximab. Modification of
elbow hinge sequences within the antibody variable
framework regions resulted in a strong apoptosis-
inducing activity of obinutuzumab. Complement and
antibody-dependent cellular cytotoxicity are believed to
be the major effector mechanisms of obinutuzumab in
whole blood assays [44]. 13 patients with relapsed or re-
fractory disease were enrolled in a phase 1 study of obi-
nutuzumab. The results showed that the ORR was 62%
Table 4 Phase 2 trials of ofatumumab monotherapy and chemoimmunotherapy in CLL patients








Wierda, 2010 [36] Ofatumumab 95 FA-ref 0 51 5.5 14.2
111 BF-ref 2 44 5.5 17.4
Flinn, 2011 [37] Ofatumumab 42 Untreated 0 44 NR NR
Wierda, 2011 [38] O-FC (500 mg) 31 Untreated 32 77 NR NR
O-FC (1000 mg) 30 Untreated 50 73 NR NR
Shanafelt, 2011 [39] PCO 33 Untreated 45 94 NR NR
Abbreviations: BF-ref, fludarabine-refractory CLL with bulky (>5 cm) lymphadenopathy; CR, complete response; FA-ref, fludarabine- and alemtuzumab-refractory;
NR, not researched; O-FC (500 mg), 500 mg ofatumumab combined with fludarabine and cyclophosphamide; O-FC (1000 mg), 1000 mg ofatumumab combined
with fludarabine and cyclophosphamide; ORR, overall response rate; OS, overall survival; PCO, pentostatin, cyclophosphamide and ofatumumab.
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ship established [45].
Immunomodulatory drugs
The encouraging antitumour activity of thalidomide in
various malignant disorders led to development of sub-
sequent analogues. The immunomodulatory agents lena-
lidomide and pomalidomide have shown promising
antineoplastic activity in various tumor types [46,47].
Lenalidomide has demonstrated clinical efficacy in CLL
through various mechanisms [48]. The results of a re-
cent study showed that lenalidomide therapy was well
tolerated and induced durable remissions in the popula-
tion of elderly, symptomatic patients with CLL [49]. In
this study, sixty patients with CLL, which were 65 years
of age and older, received treatment with lenalidomide.
At a median follow-up of 29 months, 53 patients (88%)
are alive and 32 patients (53%) remain on therapy. Esti-
mated 2-year PFS was 60%. The ORR to lenalidomide
therapy was 65%, including 10% CR, 5% CR with re-
sidual cytopenia, 7% nPR, and 43% PR. Neutropenia was
the most common grade 3 or 4 treatment-related tox-
icity observed in 34% of treatment cycles. Major infec-
tions or neutropenic fever occurred in 13% of patients.
A phase 2, 2-stage study was designed to evaluate the
combination of lenalidomide and rituximab for the initial
treatment of patients with CLL [50]. 40 patients enrolled
into arm A (age under 65), and 29 into arm B (age 65 or
older). The median age on arm A was 57 years (range
45–64) and arm B 70 years (range 65–80). The ORR to
therapy for arm A was 94%, with 20% achieving a CR and
17% a nPR. The ORR for arm B was 77% with 9% achiev-
ing a CR. Arm A patients had median follow-up of
17 months with an estimated median PFS of 19 months.
Arm B had a median follow-up of 7 months, with an
estimated 85% remaining progression free at 7 months.
Another phase 2 study of lenalidomide and rituximab in
patients with relapsed or refractory CLL indicated that
the combination of lenalidomide and rituximab led to
durable responses in patients with relapsed andrefractory CLL and was active also in patients with 17p
deletion [51]. The combination therapy with ofatumu-
mab and lenalidomide in patients with relapsed CLL was
also conducted in a phase 2 trial. 5 patients (15%)
achieved CR (including 1 CRi) and 17 patients (50%) PR,
for an ORR of 65% [52].
Lenalidomide-based consolidation for CLL patients re-
ceiving first-line chemoimmunotherapy induction
appeared to improve the quality of response and pro-
longed time to retreatment [53]. Based on early experi-
ence, lenalidomide consolidation after chemotherapy
could further improve responses in 27% of patients with
CLL. Elimination of MRD was seen in 12% of patients
treated [54].
High-Dose Methylprednisolone
High-dose methylprednisolone (HDMP) has proved to
be an active treatment in patients with relapsed/refrac-
tory CLL, including those with unfavorable cytogenetic
features by numerous studies [55-57]. A phase 2 study
combining rituximab with HDMP as a salvage regimen
for the treatment of patients with fludarabine-refractory
CLL showed an ORR of 93%, with a CR rate of 36% [58].
Another report from the same group showed a similar
efficacy in the front-line setting: an ORR of 96%, with a
CR rate of 32% using a reduced number of days of
methylprednisolone [59]. Although a lower ORR of 78%
(22% CR) was reported by a larger single-institution re-
view of 37 patients who were treated with the same
HDMP plus rituximab combination, a high response rate
was showed for those with high-risk cytogenetic abnor-
malities, including ORRs of 55.6% and 66.7% for those
with 17p deletion and 11q deletion, respectively [60].
Another study evaluated the efficacy and safety of
dose-dense HDMP plus rituximab in patients with high-
risk CLL. 29 patients with relapsed or progressive CLL
with adverse cytogenetics (17p deletion, TP53 mutation,
11q deletion, and/or trisomy 12) and/or progression
within 12 months of fludarabine treatment were
included. The ORR was 62%, and 28% of patients had
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ORR was 69%. After 22 months, the median PFS and OS
were 12 and 31 months, respectively. The most frequent
toxicity was hyperglycemia, and three deaths occurred in
the study [61]. Combination of HDMP and ofatumumab
was also demonstrated as an effective salvage treatment
for heavily pretreated, unfit or refractory patients with
CLL [62].
Cyclin-dependent kinase (CDK) inhibitors
As a broad CDK inhibitor, flavopiridol (alvocidib) could
induce apoptosis in human CLL cells and is independent
on p53 ways. Flavopiridol has demonstrated activity in
patients with relapsed CLL, including those with
high-risk genomic features and bulky lymphadenopathy
[63-65]. Outcomes of refractory CLL patients in two age
categories (≥70, <70 years) treated with single-agent fla-
vopiridol indicated that flavopiridol treatment of patients
aged 70 or older with refractory or relapsed CLL was a
feasible therapeutic approach, and may have similar effi-
cacy relative to younger patients. No significant differ-
ence between older and younger patients was observed
in response rates (43% versus 47%) or median PFS (8.7
versus 9.9 months, P > 0.80). Although median OS was
worse in older patients (2.1 versus 2.4 years, P = 0.02),
when adjusted for other factors, this difference was no
longer significant (P > 0.10). With exception to infec-
tions (older = 29% versus younger = 62%), no significant
association with toxicity was observed [66].
Activity of combined flavopiridol and lenalidomide in
patients with cytogenetically high risk CLL was observed
in a phase 1 trial. The results showed that the combin-
ation of flavopiridol and lenalidomide was well tolerated
without increased risks of tumor lysis syndrome or
tumor flare, with significant activity in patients with
bulky, cytogenetically high-risk CLL. In 23 evaluable
patients who completed 1 or more cycles of combined
lenalidomide and flavopiridol, PRs were observed in
13 patients (57%). 6 patients were able to proceed to allo-
geneic transplant after 1–3 cycles, and 4 of these patients
remain in remission. Median PFS and OS are 7 months
(range 0–24 months; 95% CI 5, 11) and 23 months (range
0–27 months; 95% CI 13, 27), respectively [67].
Other related CDK inhibitors, such as dinaciclib
(SCH 727965), BMS-387032 (SNS-032), sunitinib and
sorafenib are being investigated in patients with
relapsed or refractory CLL. In a phase 1 trial, dinaci-
clib appeared to have a similar response rate but less
toxicity than flavopiridol in patients with relapsed or
refractory CLL [68].
Bcl-2 inhibitors
Navitoclax (ABT-263) is a small-molecule BH3 mimetic
that potently inhibits BCL-2, BCL-xL, and BCL-w and isable to induce apoptosis in primary CLL cells. In a phase
1/2a trial in patients with relapsed or refractory CLL,
90% patients showed at least a 50% decrease in absolute
lymphocyte count, and the ORR was 35%, all PRs. The
median treatment duration was 7 months, with median
PFS and time to progression of 25 months. Furthermore,
the PFS was similar in fludarabine-refractory and
fludarabine-sensitive patients. However, significant tox-
icity of thrombocytopenia may limit the use of navitoclax
in heavily pretreated fludarabine-refractory CLL patients
[69,70]. Combination study has been conducted to exam-
ine whether navitoclax could be used safely in combin-
ation with FCR or bendamustine plus rituximab (BR) for
treatment of patients with CLL. Of the 16 patients
assessed in Arm B (BR), 6 achieved CR, 7 PR, 2 SD and
1 with PD. The ORR was 81% (13/16). In this arm, 3/5
patients with 17p deletion achieved PR. Of the 4 patients
assessed in Arm A (FCR), 2 achieved PR, 1 SD and 1 with
PD. The combination of navitoclax with BR appeared
well-tolerated and to have anti-tumor activity [71]. Other
Bcl-2 inhibitors included oblimersen, gossypol (AT-101),
obatoclax, SPC2996 are also in investigational phases
and further studies with these agents are warranted
[72-75].Kinase inhibitors of B-cell receptor (BCR) signaling
pathways
Phosphatidylinositol-3-kinase (PI3K) inhibitors
In lymphocytes, the PI3K isoform p110δ (PI3Kδ)
transmits signals from surface receptors, including the
B-cell receptor (BCR). GS-1101 (CAL-101), an isoform-
selective inhibitor of PI3Kδ that inhibits PI3K signaling,
which induces apoptosis of CLL cells and reduces inter-
actions that retain CLL cells in protective tissue microen-
vironments in vitro, displays clinical activity in CLL,
causing rapid lymph node shrinkage and a transient
lymphocytosis [76]. A phase 1 study of GS-1101 in 37
patients with relapsed or refractory CLL was reported
[77]. GS-1101 reduced lymphadenopathy in all of the
patients, and 91% achieved a lymph node response
(≥50% reduction in target nodal lesions). The ORR was
33% (all PRs) and the median duration of response had
not been reached. 75% of patients with CLL-related
thrombocytopenia had either an improvement to
>100,000/μL or a >50% increase from baseline. Another
phase 1 trial studied GS-1101 in combination with rituxi-
mab and/or bendamustine in 27 patients with previously
treated CLL [78]. The results indicated that GS-1101
offered major and rapid reductions in lymphadenopathy.
Recently, the preliminary data from a phase 1 trial sug-
gested that SAR245408, an oral pan-PI3K inhibitor, was
generally well tolerated in heavily pretreated relapsed/
refractory CLL [79].
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Ibrutinib (PCI-32765), a specific inhibitor of Btk, can
disrupt several signaling pathways involved in tumor
microenvironment interactions, induce apoptosis and
inhibit cellular migration and adhesion in malignant
B-cells [80]. An early analysis of the phase 1b/2 study
PCYC-1102 showed ibrutinib to be highly active and tol-
erable in patients with CLL [81]. Nodal response was
seen in 89% of patients with lymphadenopathy, with an
increase in absolute lymphocyte count in 75%. At a me-
dian follow-up of 4 months, the ORR was 44% (39% PRs,
5% CRs) and 4 of 12 patients with deletion 17p had
responded, suggesting activity in this subgroup. Longer-
term follow-up of this multicenter phase 1b/2 trial has
been recently reported [82]. Results of this analysis indi-
cated that ibrutinib was well tolerated and was associated
with high rates of 6-month PFS in relapsed or refractory
CLL/ SLL. Grade 1 or 2 diarrhea, fatigue, nausea, and
ecchymosis have been the most frequently reported ad-
verse events. Serious adverse events have occurred in
38% of patients. ORR in the 420 mg cohort was 48% with
6.2 months median follow-up and 70% with 10.2 months
median follow-up. ORR in the 840 mg cohort was 44% at
6.5 months median follow-up. An additional 19%, and
35% of patients in these cohorts, respectively, had a nPR
with residual lymphocytosis.
Spleen tyrosine kinase (Syk) inhibitors
Syk is a protein tyrosine kinase that couples BCR activa-
tion with downstream signaling pathways, promoting
cell activation and migration. In CLL, Syk could be acti-
vated by external signals from the tissue microenviron-
ment. Fostamatinib disodium (R788) is the first clinically
available oral Syk inhibitor. A multicenter phase 1/2
clinical trial of fostamatinib disodium in patients with
recurrent B-cell NHL was reported [83]. The 11 patients
with CLL/SLL enrolled in this study achieved an ORR of
55% (all PRs) and a PFS of 6.4 months. Common toxici-
ties included diarrhea, fatigue, cytopenias, hypertension,
and nausea. Preclinical studies of other Syk inhibitors
such as R406 and two highly selective Syk inhibitors
(PRT318 and P505-15) demonstrated responses in CLL
cells supporting the development of a novel and active
therapeutic approach for CLL and other selected B-cell
malignancies [84,85].
Lyn tyrosine kinase inhibitors
Dasatinib, a tyrosine kinase inhibitor originally devel-
oped as a pan-Src kinase inhibitor, can inhibit Lyn kin-
ase (a Src-family kinase) and lead to apoptosis of the
CLL cells in vitro. A phase 2 clinical trial of dasatinib
monotherapy in patients with relapsed CLL showed a
20% ORR and reported myelosuppression as the major
toxicity [86]. However, another phase 2 study of single-agent dasatinib showed a lack of efficacy in heavily pre-
treated CLL patients, with an only ORR of 6% and a
high incidence of neutropenia [87]. Bafetinib, another
Lyn kinase inhibitor, also showed efficacy in patients
with relapsed/refractory B-CLL in a phase 2 trial [88].
Hematopoietic stem cell transplantation (HSCT)
Both autologous HSCT (auto-HSCT) and allogeneic
HSCT (allo-HSCT) have been increasingly used to treat
relapsed or refractory CLL. Auto-HSCT, which solely
relies on dose intensity, does not yield better results than
modern chemoimmunotherapy. Results of a phase 3 ran-
domized trial of autografting in CLL versus observation
for 223 responding patients after first- or second-line
treatment indicated that consolidating autografting
reduced the risk of progression by more than 50% but
had no effect on OS in CLL [89]. Although early treat-
ment intensification including auto-HSCT could provide
effective disease control in poor-risk CLL, its clinical
benefit compared to FCR regimens remained uncertain
[90].
Allo-HSCT has been proven to be the only potentially
curative treatment for relapsed CLL patients with
fludarabine-refractory disease or a 17p deletion, leading
to long-term survival [91,92]. However, myeloablative
allo-HSCT showed unacceptable toxicity and mortality
in CLL patients [93,94]. Reduced-intensity conditioning
(RIC) regimens decrease high transplant-related mortal-
ity resulted from severe graft-versus-host disease and
infections. The improvement of RIC regimens allows
allo-HSCT administrated in older patients and younger
patients with co-morbidity [95]. In general, depending
on the conditioning regimen and follow-up, RIC allo-
HCT was associated with a 11% to 34% nonrelapse mor-
tality, a 34% to 67% PFS, and a 48% to 72% OS [96].
Published literature supports the use of RIC allo-HCT
for patients who fulfill acceptable consensus criteria for
hematopoietic stem cell allografting, once a suitable
donor is identified [97]. In a feasibility analysis of
patients with CLL and 17p deletion, Yvonne Hsu et al.
reviewed nonmyeloabltive allo-HSCT outcomes for 17p
deletion CLL patients transplanted between 2005 and
2010. With a median follow-up of 18 months (range,
3–60), the 2-year OS and PFS rates were 62% and
38%, respectively. Chemosensitivity was associated with
significantly higher PFS (73% versus 12%, P = 0.02)
and a trend for higher OS (91% versus 45%, P = 0.09).
Nonmyeloabltive allo-HSCT is more effective in 17p
deletion CLL patients when recipients have chemosen-
sitive disease [98].
Conclusion and future directions
Numerous treatment strategies for CLL have emerged
over the years, from the use of chlorambucil to RIC
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prognosis of CLL. Treatment must be flexible and tai-
lored for different patient groups [3]. The combination of
chemotherapy with monoclonal antibodies has further
improved response rates and is now the preferred regi-
men for younger patients requiring treatment. Nonethe-
less, allo-HSCT remains the only curative option. RIC
allo-HSCT must be strongly considered whenever feas-
ible. Newer antibodies such as anti-CD20 antibodies vel-
tuzumab, AME-133v, LFB-R603 and small modular
immunopharmaceutical (SMIP) TRU-015, anti-CD37
SMIP TRU-016, anti-CD40 antibodies dacetuzumab
(SGN-40), lucatumumab (HCD122), and novel targeted
therapeutic agents such as heat shock protein 90 inhibi-
tors SNX-7081, 17-AAG and 17-DMAG, histone deace-
tylase inhibitors depsipeptide, MS-275, valproic acid,
belinostat, MGCD0103, p53 inhibitor cenersen, murine
double minute 2 inhibitor RO5045337, and mammalian
target of rapamycin (mTOR) inhibitor RAD001, are
being investigated in early-phase clinical trials in patients
with CLL or NHL [99-111]. Such agents with novel
mechanisms of action and targeting different pathways
will open a new way to the future treatment for CLL.
Abbreviations
ATM: Ataxia telangiectasia mutated; BCR: B-cell receptor; BF-ref: Fludarabine-
refractory chronic lymphocytic leukemia with bulky (>5 cm)
lymphadenopathy; CC: Cladribine and cyclophosphamide; CCR: Clinical
complete responses; CDK: Cyclin-dependent kinase;
CFAR: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab; CHOP-
R: Cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab;
CLL: Chronic lymphocytic leukemia; CMC: Cladribine, cyclphosphamide plus
mitoxantroneshowed; CR: Complete responses; CRi: Complete responses with
incomplete blood recovery; FA-ref: Refractory to fludarabine and
alemtuzumab; FBR: Fludarabine, bendamustine, and rituximab;
FC: Fludarabine and cyclophosphamide; FCR: Fludarabine,
cyclophosphamide, and rituximab; FDA: Food and drug administration;
HDMP: High-dose methylprednisolone; HSCT: Hematopoietic stem cell
transplantation; IGHV: Immunoglobulin heavy chain variable region genes;
MRD: Minimal residual disease; mTOR: Mammalian target of rapamycin;
nPR: Nodular partial response; ORR: Overall response rate; OS: Overall survival;
PCR: Pentostatin, cyclophosphamide, and rituximab; PD: Progressive disease;
PFS: Progression-free survival; PI3K: Phosphatidylinositol-3-kinase; PR: Partial
response; RIC: Reduced-intensity conditioning; SD: Stable disease; SLL: Small
lymphocytic lymphoma; SMIP: Small modular immunopharmaceutical;
ZAP70: Zeta-chain-associated protein kinase 70.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Both authors participated in drafting and editing the manuscript. Both
authors read and approved the final manuscript.
Acknowledgements
This study was partly supported by: National Natural Science Foundation
(No. 81270598), Natural Science Foundations of Shandong Province
(No. Y2007C053, No. 2009ZRB14176 and No. ZR2012HZ003), Technology
Development Projects of Shandong Province (No. 2007GG10, and No.
2010GSF10250), Program of Shandong Medical Leading Talent, and Taishan
Scholar Foundation of Shandong Province.
Received: 3 August 2012 Accepted: 6 September 2012
Published: 16 September 2012References
1. Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 2008,
371:1017–1029.
2. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S: From
pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev
Cancer 2010, 10:37–50.
3. Maddocks KJ, Lin TS: Update in the management of chronic lymphocytic
leukemia. J Hematol Oncol 2009, 2:29.
4. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J,
Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared
with chlorambucil as primary therapy for chronic lymphocytic leukemia.
N Engl J Med 2000, 343:1750–1757.
5. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M,
Kranzhofer N, Rohrberg R, Soling U, Burkhard O, et al: First-line therapy
with fludarabine compared with chlorambucil does not result in a major
benefit for elderly patients with advanced chronic lymphocytic
leukemia. Blood 2009, 114:3382–3391.
6. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G,
Niemeyer CC: Bendamustine (Treanda) displays a distinct pattern of
cytotoxicity and unique mechanistic features compared with other
alkylating agents. Clin Cancer Res 2008, 14:309–317.
7. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R,
Juliusson G, Postner G, Gercheva L, Goranov S, et al: Phase III randomized
study of bendamustine compared with chlorambucil in previously
untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009,
27:4378–4384.
8. Kolibaba KS, Joshi AD, Sterchele JA, Forsyth M, Alwon E, Beygi H, Kennealey
GT: Demographics, Treatment Patterns, Safety, and Real-World
Effectiveness in Patients > =70 Years of Age with Chronic Lymphocytic
Leukemia Receiving Bendamustine with or without Rituximab. ASH
Annual Meeting Abstracts 2011, 118:3914.
9. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl
S, Jager U, Bergmann M, Stilgenbauer S, et al: Fludarabine plus
cyclophosphamide versus fludarabine alone in first-line therapy of
younger patients with chronic lymphocytic leukemia. Blood 2006,
107:885–891.
10. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt
AR, Hamblin T, Milligan DW, Child JA, et al: Assessment of fludarabine
plus cyclophosphamide for patients with chronic lymphocytic
leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet
2007, 370:230–239.
11. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM,
Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS: Phase III
trial of fludarabine plus cyclophosphamide compared with fludarabine
for patients with previously untreated chronic lymphocytic leukemia: US
Intergroup Trial E2997. J Clin Oncol 2007, 25:793–798.
12. Stilgenbauer S, Eichhorst BF, Busch R, Zenz T, Winkler D, Buhler A, Goede V,
Wendtner CM, Lichter P, Emmerich B, et al: Biologic and Clinical Markers
for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) -
Comprehensive Analysis of the CLL4 Trial of the GCLLSG. ASH Annual
Meeting Abstracts 2089, 2008:112.
13. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L,
Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, et al: Comparison
of cladribine plus cyclophosphamide with fludarabine plus
cyclophosphamide as first-line therapy for chronic lymphocytic
leukemia: a phase III randomized study by the Polish Adult Leukemia
Group (PALG-CLL3 Study). J Clin Oncol 2010, 28:1863–1869.
14. Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J,
Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, et al:
Cladribine alone and in combination with cyclophosphamide or
cyclophosphamide plus mitoxantrone in the treatment of progressive
chronic lymphocytic leukemia: report of a prospective, multicenter,
randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood
2006, 108:473–479.
15. Robak T, Blonski J, Jamroziak K, Calbecka M, Dwilewicz-Trojaczek J,
Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, et al: Cladribine
Alone and in Combination with Cyclophosphamide or
Cyclophosphamide and Mitoxantrone in Previously Untreated Patients
with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the
the Polish Adult Leukemia Group (PALG CLL2) Study. ASH Annual Meeting
Abstracts 2011, 118:3915.
Lu and Wang Journal of Hematology & Oncology 2012, 5:55 Page 9 of 12
http://www.jhoonline.org/content/5/1/5516. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW,
Rai K, Schiffer CA, Larson RA: Randomized phase 2 study of fludarabine
with concurrent versus sequential treatment with rituximab in
symptomatic, untreated patients with B-cell chronic lymphocytic
leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
Blood 2003, 101:6–14.
17. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA,
Rai KR, Larson RA, Byrd JC: Chemoimmunotherapy with fludarabine and
rituximab produces extended overall survival and progression-free
survival in chronic lymphocytic leukemia: long-term follow-up of CALGB
study 9712. J Clin Oncol 2011, 29:1349–1355.
18. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R,
Bone ND, Dewald GW, Lin TS, et al: Combination chemoimmunotherapy
with pentostatin, cyclophosphamide, and rituximab shows significant
clinical activity with low accompanying toxicity in previously untreated B
chronic lymphocytic leukemia. Blood 2007, 109:405–411.
19. Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR,
Zent CS, Call TG, Shanafelt TD: Pentostatin and rituximab therapy for
previously untreated patients with B-cell chronic lymphocytic leukemia.
Cancer 2010, 116:2180–2187.
20. Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek
M, Boehm KA, Zhan F, Asmar L: A Phase III trial of fludarabine,
cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide,
and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs
2012, 30:1232–1240.
21. Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger
JA, Tambaro FP, Jalayer A, Lerner S, et al: A Phase I/II Trial of Fludarabine,
Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for
Previously Treated Patients with CLL. ASH Annual Meeting Abstracts 2011,
118:3901.
22. Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van
Roye C, Koppler H: Retherapy with Bendamustine-Containing Regimens
in Patients with Relapsed/Refractory CLL and Indolent Lymphomas
Achieves High Response Rates. ASH Annual Meeting Abstracts 2011,
118:1615.
23. Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Gonzalez M,
Ferra C, Abella E, Delgado J, Garcia-Marco JA, et al: Rituximab Maintenance
In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront
Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and
Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On
Behalf of the Spanish CLL Study Group (GELLC). ASH Annual Meeting
Abstracts 2011, 118:293.
24. Jenke P, Eichhorst B, Busch R, Anheier N, Duehrsen U, Duerig J, Dreyling
MH, Bergmann M, Goebeler ME, Hurtz HJ, et al: Cyclophosphamide,
Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in
Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL
with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final
Analysis of a Phase II Study of the German CLL Study Group. ASH Annual
Meeting Abstracts 2011, 118:2860.
25. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C,
Mayer J: Alemtuzumab compared with chlorambucil as first-line therapy
for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616–5623.
26. Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P,
Mauro FR, Cascavilla N, Falchi L, et al: An Italian retrospective study on
the routine clinical use of low-dose alemtuzumab in relapsed/
refractory chronic lymphocytic leukaemia patients. Br J Haematol 2012,
156:481–489.
27. Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A,
Cortelezzi A: Low dose alemtuzumab in patients with fludarabine-
refractory chronic lymphocytic leukemia. Leuk Lymphoma 2012,
53:424–429.
28. Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Winkler D, Buhler A,
Zenz T, Mack S, Busch R, Hinke A, et al: Alemtuzumab Plus Oral
Dexamethasone. Followed by Alemtuzumab Maintenance or Allogeneic
Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II
Study of the GCLLSG and fcgcll/MW. ASH Annual Meeting Abstracts 2011,
118:2854.
29. Geisler CH, van 't Veer MM, van Putten W, Jurlander J, Walewski J,
Tjonnfjord G, Itala-Remes M, Kimby E, Kozak T, Polliack A, et al:
Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A)
Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and InducesMore and Deeper Complete Remissions in Untreated Patients with High-
Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC
Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial.
ASH Annual Meeting Abstracts 2011, 118:290.
30. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J,
Koller C, Lerner S, Kantarjian H, Wierda WG: Cyclophosphamide,
fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily
pretreated patients with chronic lymphocytic leukemia. Blood 2011,
118:2085–2093.
31. Zent CS, LaPlant BR, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay N,
Weiner GJ, Witzig TE: Pentostatin, Alemtuzumab, and Low Dose
Rituximab Is Effective Therapy for Relapsed/Refractory Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). ASH Annual
Meeting Abstracts 2011, 118:1790.
32. Delmer A, Tournilhac O, Lepretre S, Cazin B, Feugier P, Dreyfus B, Mahe B,
Leporrier M, Michallet A-S, Jaccard A, et al: Consolidation Therapy with
Subcutaneous Alemtuzumab After Induction Treatment with Oral FC
(Fludarabine and Cyclophosphamide) in Previously Untreated Patients
Aged 65–70 Years with Advanced Stage Chronic Lymphocytic Leukemia
(CLL): Final Results of a Phase II Study From the FCGCLL/WM. ASH Annual
Meeting Abstracts 2011, 118:3900.
33. Castro JE, Ariza-Serrano LM, Barajas-Gamboa JS, Diaz-Perez JA, James DF,
Ale-Ali A, Kipps TJ: Eradication of Minimal Residual Disease Using
Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus
Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission
in Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2011,
118:2866.
34. Jones JA, Stark A, Zhao W, Lin TS, Rai KR, Marcucci G, Peterson B, Larson
RA, Heerema NA, Byrd JC: Alemtuzumab Consolidation Does Not
Improve Outcome for CLL Patients with High Risk Genomic Features
on Successive CALGB Trials. ASH Annual Meeting Abstracts 2011,
118:1791.
35. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A,
Robak T, Furman RR, Hillmen P, Trneny M, et al: Ofatumumab as single-
agent CD20 immunotherapy in fludarabine-refractory chronic
lymphocytic leukemia. J Clin Oncol 2010, 28:1749–1755.
36. Wierda WG, Kipps TJ, Mayer J, Robak T, Dyer MJ, Furman RR, Hillmen P,
Stilgenbauer S, Williams CD, Trneny M, et al: Final Analysis From the
International Trial of Single-Agent Ofatumumab In Patients with
Fludarabine-Refractory Chronic Lymphocytic Leukemia. ASH Annual
Meeting Abstracts 2010, 116:921.
37. Flinn IW, Harwin WN, Macias-Perez IM, Tucker PS, Waterhouse DM, Papish
SW, Jones JA, Hainsworth JD, Byrd JC: A Phase II Trial of Ofatumumab
for Older Patients and Patients Who Refuse Fludarabine-Based
Regimens with Previously Untreated Chronic Lymphocytic Leukemia or
Small Lymphocytic Lymphoma. ASH Annual Meeting Abstracts 2011,
118:3912.
38. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej
L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, et al: Chemoimmunotherapy
with O-FC in previously untreated patients with chronic lymphocytic
leukemia. Blood 2011, 117:6450–6458.
39. Shanafelt TD, Lanasa MC, Zent CS, Leis JF, Call TG, LaPlant BR, Tun H, Bowen
DA, Jelinek DF, Hanson CA, Kay N: Ofatumumab Based
Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL.
ASH Annual Meeting Abstracts 2011, 118:3898.
40. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J,
Wynne D, Reid J, et al: Phase 1 study of lumiliximab with detailed
pharmacokinetic and pharmacodynamic measurements in patients with
relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007,
13:4448–4455.
41. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N,
Woodworth J, Hughes S, Tangri S, et al: Phase 1/2 study of lumiliximab
combined with fludarabine, cyclophosphamide, and rituximab in
patients with relapsed or refractory chronic lymphocytic leukemia. Blood
2010, 115:489–495.
42. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC: The clinical
application of monoclonal antibodies in chronic lymphocytic leukemia.
Blood 2010, 116:3705–3714.
43. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R,
Schmidt C, Gerdes C, Nopora A, et al: Novel 3rd Generation Humanized
Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow
Lu and Wang Journal of Hematology & Oncology 2012, 5:55 Page 10 of 12
http://www.jhoonline.org/content/5/1/55Hinge for Enhanced ADCC and Superior Apoptosis Induction. ASH Annual
Meeting Abstracts 2006, 108:229.
44. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M,
Golay J: Mechanism of action of type II, glycoengineered, anti-CD20
monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole
blood assays in comparison with rituximab and alemtuzumab. J Immunol
2011, 186:3762–3769.
45. Morschhauser F, Cartron G, Lamy T, Milpied N-J, Thieblemont C, Tilly H,
Weisser M, Birkett J, Salles GA: Phase I Study of RO5072759 (GA101) in
Relapsed/Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting
Abstracts 2009, 114:884.
46. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A,
Kumar S, Greipp PR, Lust JA, et al: Pomalidomide plus low-dose
dexamethasone in myeloma refractory to both bortezomib and
lenalidomide: comparison of 2 dosing strategies in dual-refractory
disease. Blood 2011, 118:2970–2975.
47. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A:
Long-term outcome of pomalidomide therapy in myelofibrosis. Am J
Hematol 2012, 87:66–68.
48. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A: Mechanism of
action of lenalidomide in hematological malignancies. J Hematol Oncol
2009, 2:36.
49. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG,
O'Brien SM, Faderl S, Kornblau SM, et al: Lenalidomide as initial therapy of
elderly patients with chronic lymphocytic leukemia. Blood 2011,
118:3489–3498.
50. James DF, Brown JR, Werner L, Wierda WG, Barrientos JC, Castro J, Greaves
A, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ: Lenalidomide and Rituximab
for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia
(CLL) A Multicenter Study of the CLL Research Consortium. ASH Annual
Meeting Abstracts 2011, 118:291.
51. Badoux XC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M,
Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A: Final Analysis of a Phase 2
Study of Lenalidomide and Rituximab in Patients with Relapsed or
Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting
Abstracts 2011, 118:980.
52. Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E,
Smith SC, Ayala AB, Falchi L, et al: Combination Therapy with
Ofatumumab and Lenalidomide in Patients with Relapsed Chronic
Lymphocytic Leukemia (CLL): Results of a Phase II Trial. ASH Annual
Meeting Abstracts 2011, 118:1788.
53. Shanafelt TD, Tun H, Hanson CA, Zent CS, Leis JF, Call TG, LaPlant BR,
Bowen D, Pavey ES, Jelinek DF, Kay N: Lenalidomide Consolidation
Appears to Prolong Time to Retreatment After First-Line
Chemoimmunotherapy for Patients with Previously Untreated CLL. ASH
Annual Meeting Abstracts 2011, 118:3899.
54. Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL,
Calin S, Wang S, Lerner S, Ferrajoli A: Initial Experience with Lenalidomide
As Consolidation Treatment in Patients with Chronic Lymphocytic
Leukemia and Residual Disease After Chemotherapy. ASH Annual Meeting
Abstracts 2011, 118:3907.
55. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D:
Methylprednisolone in advanced chronic lymphocytic leukaemia:
rationale for, and effectiveness of treatment suggested by DiSC assay.
Acta Haematol 1995, 93:73–79.
56. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D:
High dose methyl prednisolone in refractory chronic lymphocytic
leukaemia. Leuk Lymphoma 1999, 34:167–170.
57. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H,
Ropner JE, Joshi R, Mackie PH, Douglas ID, Bowcock SJ, Catovsky D:
High dose methylprednisolone can induce remissions in CLL
patients with p53 abnormalities. Ann Hematol 2003,
82:759–765.
58. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ: Rituximab in
combination with high-dose methylprednisolone for the treatment of
fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia
2008, 22:2048–2053.
59. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ:
Rituximab in combination with high-dose methylprednisolone for the
treatment of chronic lymphocytic leukemia. Leukemia 2009, 23:1779–1789.60. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL,
Jelinek DF, Kay NE, Shanafelt TD: Methylprednisolone-rituximab is an
effective salvage therapy for patients with relapsed chronic lymphocytic
leukemia including those with unfavorable cytogenetic features. Leuk
Lymphoma 2007, 48:2412–2417.
61. Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J,
Degulys A, Zvirblis T, Griskevicius L: Dose-dense high-dose
methylprednisolone and rituximab in the treatment of relapsed or
refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma 2011,
52:1055–1065.
62. Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, Paz RN, Bernal-Corzo C, Ale-
Ali A, James DF, Kipps TJ: Ofatumumab and High-Dose
Methylprednisolone Is An Effective Salvage Treatment for Heavily
Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic
Leukemia: Single Institution Experience.. ASH Annual Meeting Abstracts
2010, 116:4638.
63. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA,
Blum KA, Flynn JM, Jones JA, Hu W, et al: Phase II study of flavopiridol
in relapsed chronic lymphocytic leukemia demonstrating high
response rates in genetically high-risk disease. J Clin Oncol 2009,
27:6012–6018.
64. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Larson R,
Kipps TJ, Leblond V, Milligan D, Janssens A, et al: Interim Analysis of
EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol),
Demonstrates Clinical Responses Among Patients with Fludarabine
Refractory CLL. ASH Annual Meeting Abstracts 2010, 116:58.
65. Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever
MR, Byrd JC, Heerema NA: Response, Progression-Free Survival, and
Overall Survival of Patients with Relapsed or Refractory Chronic
Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor
Risk Cytogenetic Abnormalities. ASH Annual Meeting Abstracts 2010,
116:2456.
66. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J,
Phelps MA, Grever MR, Byrd JC: Flavopiridol treatment of patients aged
70 or older with refractory or relapsed chronic lymphocytic leukemia
is a feasible and active therapeutic approach. Haematologica 2012,
97:423–427.
67. Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X,
Rozewski D, Phelps M, Johnson AJ, et al: Activity of Combined Flavopiridol
and Lenalidomide in Patients with Cytogenetically High Risk Chronic
Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial. ASH
Annual Meeting Abstracts 2011, 118:3910.
68. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E,
Poon J, Small K, Statkevich P, et al: Update on the Phase I Study of the
Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients
with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL):
Confirmation of Clinical Activity and Feasibility of Long-Term
Administration. ASH Annual Meeting Abstracts 2010, 116:1396.
69. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Carney D,
Xiong H, Cui Y, Busman T, Enschede S, et al: An Ongoing Phase 1/2a
Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor
Activity in Patients (pts) with Relapsed or Refractory Chronic
Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2009,
114:883.
70. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney
DA, He SZ, Huang DC, Xiong H, et al: Substantial susceptibility of chronic
lymphocytic leukemia to BCL2 inhibition: results of a phase I study of
navitoclax in patients with relapsed or refractory disease. J Clin Oncol
2012, 30:488–496.
71. Kipps TJ, Swinnen LJ, Wierda WG, Jones JA, Coutre SE, Smith MR, Yang J,
Cui Y, Busman T, Enschede S, Humerickhouse R: Navitoclax (ABT-263) Plus
Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/
Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory
Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2011,
118:3904.
72. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-
Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR: 5-year survival in patients
with relapsed or refractory chronic lymphocytic leukemia in a
randomized, phase III trial of fludarabine plus cyclophosphamide with or
without oblimersen. J Clin Oncol 2009, 27:5208–5212.
Lu and Wang Journal of Hematology & Oncology 2012, 5:55 Page 11 of 12
http://www.jhoonline.org/content/5/1/5573. Balakrishnan K, Burger JA, Wierda WG, Gandhi V: AT-101 induces apoptosis
in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and
drug resistance. Blood 2009, 113:149–153.
74. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J,
Cheson BD: Phase I study of obatoclax mesylate (GX15-070), a small
molecule pan-Bcl-2 family antagonist, in patients with advanced chronic
lymphocytic leukemia. Blood 2009, 113:299–305.
75. Durig J, Duhrsen U, Klein-Hitpass L, Worm J, Hansen JB, Orum H,
Wissenbach M: The novel antisense Bcl-2 inhibitor SPC2996 causes rapid
leukemic cell clearance and immune activation in chronic lymphocytic
leukemia. Leukemia 2011, 25:638–647.
76. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating
MJ, Giese N, O'Brien S, Yu A, Miller LL, et al: The phosphoinositide 3'-kinase
delta inhibitor, CAL-101, inhibits B-cell receptor signaling and
chemokine networks in chronic lymphocytic leukemia. Blood 2011,
118:3603–3612.
77. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, Wagner-Johnston
ND, Flinn IW, Kahl BS, Spurgeon SE, Lannutti B, et al: CAL-101, An Isoform-
Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta},
Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients
with Relapsed or Refractory Chronic Lymphocytic Leukemia. ASH Annual
Meeting Abstracts 2010, 116:55.
78. Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, Schreeder
MT, Barrientos JC, Wagner-Johnston ND, Boyd T, et al: A Phase 1 Study of
the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor,
CAL-101 (GS-1101), in Combination with Rituximab and/or
Bendamustine in Patients with Relapsed or Refractory Chronic
Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2011,
118:1787.
79. Brown JR, Davids MS, Rodon J, Abrisqueta P, DeCillis AP, Rockich K, Egile C,
Kelly A, Xu Y, Lager J, Awan FT: Phase I Trial of SAR245408 (S08), a Pan-
Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic
Lymphocytic Leukemia (CLL) and Lymphoma. ASH Annual Meeting
Abstracts 2011, 118:2683.
80. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST,
Spaargaren M: The clinically active BTK inhibitor PCI-32765 targets B-cell
receptor- and chemokine-controlled adhesion and migration in chronic
lymphocytic leukemia. Blood 2012, 119:2590–2594.
81. Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW,
Grant BW, Richards DA, Zhao W, et al: Activity and tolerability of the
Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL):
Interim results of a phase Ib/II study. ASCO Meeting Abstracts 2011,
29:6508.
82. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW,
Grant B, Heerema NA, Johnson AJ, et al: The Bruton's Tyrosine Kinase
(BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or
Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. ASH Annual
Meeting Abstracts 2011, 118:983.
83. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A,
Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, et al: Inhibition of Syk
with fostamatinib disodium has significant clinical activity in non-
Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010,
115:2578–2585.
84. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda
WG, Gandhi V, Burger JA: B-cell antigen receptor signaling enhances
chronic lymphocytic leukemia cell migration and survival: specific
targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood
2009, 114:1029–1037.
85. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi
F, Wierda WG, O'Brien S, Keating MJ, Burger JA: Selective, novel spleen
tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia
B-cell activation and migration. Leukemia 2012, 26:1576–1583.
86. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher
DC, Lacasce AS, Jacobsen ED, Armand P, et al: Phase II study of dasatinib
in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res
2011, 17:2977–2986.
87. Al-Ameri AM, Badoux X, Ferrajoli A, Wierda WG, Fayad L, Estrov Z, Bickel S,
Keating MJ, O'Brien S: Phase II Study of Dasatinib In Patients withRelapsed Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts
2010, 116:4488.
88. Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA,
Wieland S, Levitt D: A Pilot Phase II Study of the Lyn Kinase Inhibitor
Bafetinib in Patients with Relapsed or Refractory B Cell Chronic
Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2011, 118:2858.
89. Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M,
Choquet S, Corront B, Dearden C, et al: Autologous hematopoietic stem
cell transplantation in chronic lymphocytic leukemia: results of European
intergroup randomized trial comparing autografting versus observation.
Blood 2011, 117:1516–1521.
90. Dreger P, Dohner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM,
Knauf W, Stadler M, Pfreundschuh M, et al: Early autologous stem cell
transplantation for chronic lymphocytic leukemia: long-term follow-up
of the German CLL Study Group CLL3 trial. Blood 2012, 119:4851–4859.
91. Caballero D, Garcia-Marco JA, Martino R, Mateos V, Ribera JM, Sarra J, Leon
A, Sanz G, de la Serna J, Cabrera R, et al: Allogeneic transplant with
reduced intensity conditioning regimens may overcome the poor
prognosis of B-cell chronic lymphocytic leukemia with unmutated
immunoglobulin variable heavy-chain gene and chromosomal
abnormalities (11q- and 17p-). Clin Cancer Res 2005, 11:7757–7763.
92. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch
F, Lopez-Guillermo A, Campo E, Sierra J, Montserrat E: Allogeneic stem-cell
transplantation may overcome the adverse prognosis of unmutated VH
gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005,
23:3433–3438.
93. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR,
Carston M, Giralt S, Molina A, Copelan EA, et al: Unrelated donor
marrow transplantation for B-cell chronic lymphocytic leukemia after
using myeloablative conditioning: results from the Center for
International Blood and Marrow Transplant research. J Clin Oncol 2005,
23:5788–5794.
94. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo
SR, Stein RS, Bociek G, Greer JP, Wu CD, et al: Outcome of allogeneic stem
cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow
Transplant 2000, 25:717–722.
95. Dreger P: Allotransplantation for chronic lymphocytic leukemia.
Hematology / the Education Program of the American Society of Hematology
American Society of Hematology Education Program 2009, 1:602–609.
96. Delgado J, Milligan DW, Dreger P: Allogeneic hematopoietic cell
transplantation for chronic lymphocytic leukemia: ready for prime time?
Blood 2009, 114:2581–2588.
97. Kharfan-Dabaja MA, Bazarbachi A: Hematopoietic stem cell allografting for
chronic lymphocytic leukemia: a focus on reduced-intensity conditioning
regimens. Cancer control: journal of the Moffitt Cancer Center 2012, 19:68–75.
98. Hsu Y, Saliba RM, Okoroji G-J, o'Brien S, Ferrajoli A, Abruzzo LV, Champlin R,
Keating MJ, Khouri IF: Feasibility Analysis of Nonmyeloabltive Allogeneic
Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic
Leukemia (CLL) and 17p- Deletion. ASH Annual Meeting Abstracts 2011,
118:4123.
99. Milani C, Castillo J: Veltuzumab, an anti-CD20 mAb for the treatment of
non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune
thrombocytopenic purpura. Curr Opin Mol Ther 2009, 11:200–207.
100. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang
NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, et al: Results of a phase
1 study of AME-133v (LY2469298), an Fc-engineered humanized
monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients
with previously treated follicular lymphoma. Clin Cancer Res 2012,
18:1395–1403.
101. Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B:
The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-kappaB/
Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to
TRAIL apoptosis. Int J Oncol 2011, 38:1683–1694.
102. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan
P, Bader R, Slater S, Nilsson CA, Barone DS, et al: CD20-directed small
modular immunopharmaceutical, TRU-015, depletes normal and
malignant B cells. Clin Cancer Res 2009, 15:2739–2746.
103. Robak T, Robak P, Smolewski P: TRU-016, a humanized anti-CD37 IgG
fusion protein for the potential treatment of B-cell malignancies. Curr
Opin Investig Drugs 2009, 10:1383–1390.
Lu and Wang Journal of Hematology & Oncology 2012, 5:55 Page 12 of 12
http://www.jhoonline.org/content/5/1/55104. Furman RR, Forero-Torres A, Shustov A, Drachman JG: A phase I study of
dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in
patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010,
51:228–235.
105. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic
S, Dey J, Baeck J, O'Brien S: Phase I study of the anti-CD40 humanized
monoclonal antibody lucatumumab (HCD122) in relapsed chronic
lymphocytic leukemia. Leuk Lymphoma 2012, in press.
106. Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP: The
Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to
fludarabine in chronic lymphocytic leukemia cells with lesions in the
TP53 pathway: a potential treatment strategy for fludarabine refractory
disease. Leuk Lymphoma 2012, 53:1367–1375.
107. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, Goettl
VM, Zhang X, Jarjoura D, Raymond CA, et al: 17-DMAG targets the nuclear
factor-kappaB family of proteins to induce apoptosis in chronic
lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood
2010, 116:45–53.
108. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors
in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5.
109. Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM,
Friedman DR, Diehl LF, Rehder C, et al: Phase II study of cenersen, an
antisense inhibitor of p53, in combination with fludarabine,
cyclophosphamide and rituximab for high-risk chronic lymphocytic
leukemia. Leuk Lymphoma 2012, 53:218–224.
110. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics:
inhibitors of MDM2. ALK and PARP. Journal of hematology & oncology
2011, 4:16.
111. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C: A
pilot trial of the mTOR (mammalian target of rapamycin) inhibitor
RAD001 in patients with advanced B-CLL. Ann Hematol 2009, 88:221–227.
doi:10.1186/1756-8722-5-55
Cite this article as: Lu and Wang: Therapeutic advancement of chronic
lymphocytic leukemia. Journal of Hematology & Oncology 2012 5:55.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
